vs
Side-by-side financial comparison of Cycurion, Inc. (CYCU) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $3.5M, roughly 1.3× Cycurion, Inc.). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -141.2%, a 115.7% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs -13.1%). NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-3.5M). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs -8.6%).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
CYCU vs NBY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $3.5M | $4.8M |
| Net Profit | $-5.0M | $-1.2M |
| Gross Margin | 12.1% | 65.2% |
| Operating Margin | -141.7% | -37.2% |
| Net Margin | -141.2% | -25.5% |
| Revenue YoY | -13.1% | 126.1% |
| Net Profit YoY | -546.8% | 70.5% |
| EPS (diluted) | $-11.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.5M | — | ||
| Q3 25 | $3.8M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $3.9M | — | ||
| Q4 24 | $4.1M | $4.8M | ||
| Q3 24 | $4.5M | $0 | ||
| Q2 24 | $5.0M | $2.4M | ||
| Q1 24 | $4.2M | $2.6M |
| Q4 25 | $-5.0M | — | ||
| Q3 25 | $-3.1M | — | ||
| Q2 25 | $-5.3M | — | ||
| Q1 25 | $-10.2M | — | ||
| Q4 24 | $1.1M | $-1.2M | ||
| Q3 24 | $116.1K | $-1.2M | ||
| Q2 24 | $306.1K | $-1.6M | ||
| Q1 24 | $-312.5K | $-3.2M |
| Q4 25 | 12.1% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 17.5% | — | ||
| Q4 24 | 37.9% | 65.2% | ||
| Q3 24 | 16.1% | — | ||
| Q2 24 | 20.5% | 66.3% | ||
| Q1 24 | 8.2% | 68.2% |
| Q4 25 | -141.7% | — | ||
| Q3 25 | -118.2% | — | ||
| Q2 25 | -96.9% | — | ||
| Q1 25 | -260.9% | — | ||
| Q4 24 | 31.9% | -37.2% | ||
| Q3 24 | 9.4% | — | ||
| Q2 24 | 14.6% | -67.4% | ||
| Q1 24 | -0.8% | -87.1% |
| Q4 25 | -141.2% | — | ||
| Q3 25 | -81.5% | — | ||
| Q2 25 | -136.1% | — | ||
| Q1 25 | -264.8% | — | ||
| Q4 24 | 27.5% | -25.5% | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 6.1% | -66.0% | ||
| Q1 24 | -7.4% | -122.2% |
| Q4 25 | $-11.09 | — | ||
| Q3 25 | $-1.59 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.56 | — | ||
| Q4 24 | $1.56 | — | ||
| Q3 24 | $0.11 | $-1.92 | ||
| Q2 24 | $0.01 | $-1.37 | ||
| Q1 24 | $-0.02 | $-29.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3M | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.1M | $-129.0K |
| Total Assets | $33.5M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3M | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $1.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $38.7K | $430.0K | ||
| Q3 24 | — | $776.0K | ||
| Q2 24 | — | $751.0K | ||
| Q1 24 | — | $1.8M |
| Q4 25 | $20.1M | — | ||
| Q3 25 | $19.1M | — | ||
| Q2 25 | $14.0M | — | ||
| Q1 25 | $12.9M | — | ||
| Q4 24 | $3.5M | $-129.0K | ||
| Q3 24 | $-3.7M | $1.1M | ||
| Q2 24 | $-3.4M | $-617.0K | ||
| Q1 24 | $-2.8M | $160.0K |
| Q4 25 | $33.5M | — | ||
| Q3 25 | $32.3M | — | ||
| Q2 25 | $30.7M | — | ||
| Q1 25 | $31.5M | — | ||
| Q4 24 | $25.6M | $3.4M | ||
| Q3 24 | $2.9M | $3.9M | ||
| Q2 24 | $2.7M | $3.9M | ||
| Q1 24 | $3.1M | $5.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-1.7M |
| Free Cash FlowOCF − Capex | $-3.5M | $-1.7M |
| FCF MarginFCF / Revenue | -98.8% | -35.4% |
| Capex IntensityCapex / Revenue | 5.3% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.3M | — | ||
| Q3 25 | $-2.5M | — | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $-2.7M | — | ||
| Q4 24 | $-205.7K | $-1.7M | ||
| Q3 24 | $-315.2K | $-2.4M | ||
| Q2 24 | $-578.0K | $-1.4M | ||
| Q1 24 | $-272.4K | $-2.0M |
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-2.6M | — | ||
| Q2 25 | $-3.7M | — | ||
| Q1 25 | $-2.8M | — | ||
| Q4 24 | $-310.7K | $-1.7M | ||
| Q3 24 | $-420.2K | — | ||
| Q2 24 | $-711.0K | — | ||
| Q1 24 | $-377.4K | $-2.0M |
| Q4 25 | -98.8% | — | ||
| Q3 25 | -66.9% | — | ||
| Q2 25 | -94.2% | — | ||
| Q1 25 | -72.7% | — | ||
| Q4 24 | -7.6% | -35.4% | ||
| Q3 24 | -9.4% | — | ||
| Q2 24 | -14.2% | — | ||
| Q1 24 | -8.9% | -75.3% |
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.6% | 0.1% | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.7% | 0.0% | ||
| Q1 24 | 2.5% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.18× | — | ||
| Q3 24 | -2.71× | — | ||
| Q2 24 | -1.89× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CYCU
Segment breakdown not available.
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
